Placenta Percreta, Third TrimesterNCT06849349
Placenta Previa and Placenta Percreta Patients During the Third Trimester
An observational study of Placenta Percreta, Third Trimester and Placenta Previa, run by Manisa Celal Bayar University at 1 site in Turkey (Türkiye).
Trial summary
Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the… Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Placenta Percreta, Third Trimester, Placenta Previa
- How many people
- 48 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Feb 2025to 20 Nov 2025
- How long will I take part?
- 11 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: women of Placenta percreata woman of Placenta previa
Who may be able to join
- Healthy pregnancy under 37 weeks
- Age range 18-50
- Being literate in Turkish
- Not having any additional disease
- Agreeing to participate in the study
Who cannot join
- High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.)
- Multiple pregnancy
- Pregnant women under the age of 18
- Smoking
- Medication use (excluding routinely used food supplements during pregnancy)
- Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.)
Show all 12Show fewer
- Immunosuppressive use
- Presence of active or chronic infection
- Presence of active or chronic inflammatory disease
- Patients who gave birth at an external center or later chose to withdraw from the study
- Patients who did not have any exclusion criteria at the time of Placenta percrata/ placenta previa or when blood was drawn for the control group, but who later developed any exclusion criteria.
- Premature birth of patients included in the control group
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of the Expression of Glycoproteins, Collagen, and Growth Factors in Patients With Placenta Previa and Placenta Percreta During the Third Trimester of Pregnancy
Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the presence of bleeding. Studies show that the increased frequency of placenta previa is associated with increased cesarean section rates and maternal age (1). Furthermore, the effects of placenta previa on maternal and fetal morbidity can be reduced with proper management (2).
Placenta percreata is a condition in which the placenta invades the myometrium (uterine muscle) and serosa (outer surface of the uterus). This can make postpartum detachment of the placenta difficult, leading to severe bleeding and complications. Placenta perforata is often associated with placenta previa and may require surgical intervention. Ultrasonography and magnetic resonance imaging (MRI) are used to diagnose this condition. Risk factors include previous cesarean deliveries and placenta previa (3). Placenta percreata requires careful management as it increases the risk of maternal mortality and morbidity (4).
In this study, we aimed to investigate the levels of decorin, laminin, collagen-1, TGFβ-1, PDGF in placentas of pregnant women with placenta percreata and previa.
Read the detailed description
In the hospital, blood tests are routinely taken preoperatively from patients hospitalized for placenta percreata and preavia. Blood samples of patients who do not have exclusion criteria and who agree to participate in the study will also be studied from routinely collected blood samples. During the hospitalization of these patients for delivery, following the clamping of the umbilical cord after the birth of the baby (after the bond between the mother and the baby is terminated), 2 ml (one teaspoon) of blood sample will be taken from the cord blood, centrifuged and the serum sample will be separated and stored at -80 degrees. A 3x3 cm piece will be taken from the umbilical cord and placenta (the baby's mate), which will be disposed of as medical waste in the postnatal process, covering all layers. The tissue samples will be placed in a container with 10% formol and preserved. At the time of umbilical cord blood and placenta sampling, these tissues are in a waste state and have no connection with the baby and mother, so there is no harm to the mother or baby during sampling. Tissues (placenta, umbilical cord) and 2 ml (one teaspoon) of blood sample from umbilical cord blood will be taken, centrifuged and serum sample will be separated and stored at -80 degrees Celsius to be used in other similar studies and projects planned to be carried out in the future.
Patients to be selected for the control group will be determined according to the exclusion criteria and will be selected with a similar gestational week and gravida number as the case group (In other studies in the literature, control group patients were collected using this similarity). If the patients selected for the control group give birth at term, tissue samples will be taken. Umbilical cord blood will be collected and stored at -80 and included in the study.
If the patient selected for the control group gives birth prematurely, gives birth in an external center or requests to withdraw from the study, the patient will be excluded from the study.
- Keywords
- Placenta Percreata, Plaenta Previa, GLYCOPROTEIN, FIBER, GROWTH FACTORS
- Medical subject headings
- Placenta Accreta, Placenta Previa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Pregnant women with Placenta Percreata | Not described | |
| Group 2: Pregnant women with Placenta Previa | Not described | |
| Group 3: Control | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Percreta Tissues
Placental tissue samples obtained at delivery from patients with placenta percreta will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.
Measured: Baseline
Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Percreta Pregnancies
Maternal and cord blood samples collected from pregnancies complicated by placenta percreta will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.
Measured: Baseline
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Previa Tissues
Placental tissue samples obtained at delivery from patients with placenta previa will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.
Measured: baseline
Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Previa Pregnancies
Maternal and cord blood samples collected from pregnancies complicated by placenta previa will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2025
- Study start20 Feb 2025
- Primary completion20 Jun 2025
- Study completion20 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placenta Percreta, Third TrimesterStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 48 participants (actual)
- Target duration
- 11 Months
Sponsor and investigators
- Lead sponsor
- Manisa Celal Bayar University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06849349
- Sponsor's protocol ID
- MCBU- Perkreata-previa
- Status last verified
- May 2026
- First submitted
- 22 Feb 2025
- Last updated
- 20 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Expression of Glycoproteins, Collagen, and Growth Factors in Patients With Placenta Previa and Placenta Percreta During the Third Trimester of Pregnancy
- ClinicalTrials.gov ID
- NCT06849349
- Acronym / sponsor ID
- MCBU- Perkreata-previa
- Keywords
- Placenta Percreata, Plaenta Previa, GLYCOPROTEIN, FIBER, GROWTH FACTORS
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Manisa Celal Bayar UniversityUniversity, hospital or other
- Study start
- 20 Feb 2025 (actual)
- Primary completion
- 20 Jun 2025 (actual)
- Study completion
- 20 Nov 2025 (actual)
- First posted
- 27 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the presence of bleeding. Studies show that the increased frequency of placenta previa is associated with increased cesarean section rates and maternal age (1). Furthermore, the effects of placenta previa on maternal and fetal morbidity can be reduced with proper management (2).
Placenta percreata is a condition in which the placenta invades the myometrium (uterine muscle) and serosa (outer surface of the uterus). This can make postpartum detachment of the placenta difficult, leading to severe bleeding and complications. Placenta perforata is often associated with placenta previa and may require surgical intervention. Ultrasonography and magnetic resonance imaging (MRI) are used to diagnose this condition. Risk factors include previous cesarean deliveries and placenta previa (3). Placenta percreata requires careful management as it increases the risk of maternal mortality and morbidity (4).
In this study, we aimed to investigate the levels of decorin, laminin, collagen-1, TGFβ-1, PDGF in placentas of pregnant women with placenta percreata and previa.
Detailed description
In the hospital, blood tests are routinely taken preoperatively from patients hospitalized for placenta percreata and preavia. Blood samples of patients who do not have exclusion criteria and who agree to participate in the study will also be studied from routinely collected blood samples. During the hospitalization of these patients for delivery, following the clamping of the umbilical cord after the birth of the baby (after the bond between the mother and the baby is terminated), 2 ml (one teaspoon) of blood sample will be taken from the cord blood, centrifuged and the serum sample will be separated and stored at -80 degrees. A 3x3 cm piece will be taken from the umbilical cord and placenta (the baby's mate), which will be disposed of as medical waste in the postnatal process, covering all layers. The tissue samples will be placed in a container with 10% formol and preserved. At the time of umbilical cord blood and placenta sampling, these tissues are in a waste state and have no connection with the baby and mother, so there is no harm to the mother or baby during sampling. Tissues (placenta, umbilical cord) and 2 ml (one teaspoon) of blood sample from umbilical cord blood will be taken, centrifuged and serum sample will be separated and stored at -80 degrees Celsius to be used in other similar studies and projects planned to be carried out in the future.
Patients to be selected for the control group will be determined according to the exclusion criteria and will be selected with a similar gestational week and gravida number as the case group (In other studies in the literature, control group patients were collected using this similarity). If the patients selected for the control group give birth at term, tissue samples will be taken. Umbilical cord blood will be collected and stored at -80 and included in the study.
If the patient selected for the control group gives birth prematurely, gives birth in an external center or requests to withdraw from the study, the patient will be excluded from the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 11 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group 1: Pregnant women with Placenta Percreata | – | – |
| Group 2: Pregnant women with Placenta Previa | – | – |
| Group 3: Control | – | – |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- women of Placenta percreata woman of Placenta previa
Key inclusion criteria (5 listed)
- Healthy pregnancy under 37 weeks
- Age range 18-50
- Being literate in Turkish
- Not having any additional disease
- Agreeing to participate in the study
Key exclusion criteria (12 listed)
- High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Percreta Tissues
Time frame: Baseline
Placental tissue samples obtained at delivery from patients with placenta percreta will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.
Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Percreta Pregnancies
Time frame: Baseline
Maternal and cord blood samples collected from pregnancies complicated by placenta percreta will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Previa Tissues
Time frame: baseline
Placental tissue samples obtained at delivery from patients with placenta previa will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.
Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Previa Pregnancies
Time frame: baseline
Maternal and cord blood samples collected from pregnancies complicated by placenta previa will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Percreta, Third Trimester and Placenta Previa, run by Manisa Celal Bayar University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Percreta Tissues (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.